Venetoclax penetrates in cerebrospinal fluid and may be
effective in chronic lymphocytic leukemia with central nervous
system involvement

J 2019

Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA et. al.

Základní údaje

Originální název

Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

Autoři

REDA, Gianluigi (380 Itálie), Ramona CASSIN (380 Itálie), Gabriela DOVRTĚLOVÁ (203 Česká republika, garant, domácí), Cristina MATTEO, Juri GIANNOTTA (380 Itálie), Maurizio D'INCALCI (380 Itálie), Agostino CORTELEZZI (380 Itálie) a Massimo ZUCCHETTI (380 Itálie)

Vydání

Haematologica, Itálie, Ferrata Storti Foundation, 2019, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.116

Kód RIV

RIV/00216224:14110/19:00109502

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3324/haematol.2018.213157

UT WoS

000466305600012

Klíčová slova anglicky

CNS involvement; Chronic Lymphocytic Leukemia; venetoclax

Štítky

EDITORIAL, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 3. 2021 14:34, Mgr. Tereza Miškechová

Anotace

V originále

Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)

Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Citovat

REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI a Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. Itálie: Ferrata Storti Foundation, 2019, roč. 104, č. 5, s. "E222-E223", 2 s. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.213157.

@article{1524093,
   author = {Reda, Gianluigi and Cassin, Ramona and Dovrtělová, Gabriela and Matteo, Cristina and Giannotta, Juri and D'Incalci, Maurizio and Cortelezzi, Agostino and Zucchetti, Massimo},
   article_location = {Itálie},
   article_number = {5},
   doi = {http://dx.doi.org/10.3324/haematol.2018.213157},
   keywords = {CNS involvement; Chronic Lymphocytic Leukemia; venetoclax},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement},
   url = {http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract},
   volume = {104},
   year = {2019}
}

TY  - JOUR
ID  - 1524093
AU  - Reda, Gianluigi - Cassin, Ramona - Dovrtělová, Gabriela - Matteo, Cristina - Giannotta, Juri - D'Incalci, Maurizio - Cortelezzi, Agostino - Zucchetti, Massimo
PY  - 2019
TI  - Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
JF  - Haematologica
VL  - 104
IS  - 5
SP  - "E222-E223"
EP  - "E222-E223"
PB  - Ferrata Storti Foundation
SN  - 03906078
KW  - CNS involvement
KW  - Chronic Lymphocytic Leukemia
KW  - venetoclax
UR  - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
L2  - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
N2  - Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
ER  -

REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI a Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. \textit{Haematologica}. Itálie: Ferrata Storti Foundation, 2019, roč.~104, č.~5, s.~''E222-E223'', 2 s. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.213157.

Podrobný výpis o publikaci